The expression of PD-L1 on tumor cells increases along disease progression due to cancer immune escape, epithelial–mesenchymal transition, or the upregulation of the JAK-STAT, MAPK, and PI3K-AKT signaling pathways [30–32]. This evidence concerns the gene AKT1 and cancer.